Comment by btilly

The problem is that the top researchers in the field have spent their lives devoted to amyloid beta. They may well have helped direct hundreds of millions in grants to this line of research.

The idea that they have blocked the treatment of Alzheimer's rather than helping it, is very, very painful. This is perfect for creating cognitive dissonance.

And so, no matter what the evidence, they remain committed to the conclusion.

As a result, the latest Alzheimer's drug to enter stage 3 FDA trials is Trontinemab. (It is currently in stage 3.) It targets the amyloid target.

A relative drop in the bucket is going to, say, the infection hypothesis. This despite the fact that the only intervention that has been shown to reduce the incidence of Alzheimer's, is the shingles vaccine.